These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33808215)

  • 1. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
    Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.
    Perry J; Ashford B; Thind AS; Gauthier ME; Minaei E; Major G; Iyer NG; Gupta R; Clark J; Ranson M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.
    Mei XL; Zhong S
    Chin Med J (Engl); 2019 Feb; 132(4):454-465. PubMed ID: 30707166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
    Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
    Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
    Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
    Meister KS; Godse NR; Khan NI; Hedberg ML; Kemp C; Kulkarni S; Alvarado D; LaVallee T; Kim S; Grandis JR; Duvvuri U
    Sci Rep; 2019 Jun; 9(1):9130. PubMed ID: 31235758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of the LY294002 - A Non-Selective Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) Pathway- in Cell Survival and Proliferation in Cell Line SCC-25.
    Duarte A; Silveira GG; Soave DF; Costa JPO; Silva AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3377-3383. PubMed ID: 31759362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation.
    Zhou K; Wu C; Cheng W; Zhang B; Wei R; Cheng D; Li Y; Cao Y; Zhang W; Yao Z; Zhang X
    Cell Death Dis; 2024 Apr; 15(4):252. PubMed ID: 38589352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
    Dienstmann R; Rodon J; Serra V; Tabernero J
    Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
    Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
    Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artesunate restrains the malignant progression of human cutaneous squamous cell carcinoma cells via the suppression of the PI3K/AKT pathway.
    Huang X; Zhang S; Wang W
    Tissue Cell; 2022 Jun; 76():101789. PubMed ID: 35338984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of Akt by methanol extracts of Impatiens balsamina L. promotes apoptosis in human oral squamous cell carcinoma cell lines.
    Shin JA; Ryu MH; Kwon KH; Choi B; Cho SD
    J Oral Pathol Med; 2015 Jul; 44(6):420-8. PubMed ID: 25212570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
    Zou Y; Ge M; Wang X
    Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway.
    Ci C; Wu C; Lyu D; Chang X; He C; Liu W; Chen L; Ding W
    Clin Exp Dermatol; 2020 Mar; 45(2):194-201. PubMed ID: 31419330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
    Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
    Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
    Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
    Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.